The recurring symptoms are usually milder than the initial illness—but you may still be contagious. By Julia Ries Some patients who have taken Pfizer's Paxlovid medication—an antiviral drug used to prevent severe illness from COVID-19—have experienced a recurrence in...
There’s plenty more to learn about the lifesaving antiviral COVID treatment. By Rachel Gutman The first data on Paxlovid, out last November, hinted that the COVID antiviral would cut the risk of hospitalization and death by 89 percent. Pundits called the drug...
By Zoey Becker The FDA rebuked Pfizer CEO Albert Bourla’s proposed solution to reports that some patients experienced a relapse of COVID-19 symptoms after treatment with the company's antiviral Paxlovid. After reports said some patients who took Paxlovid rebounded and...
Famotidine, the over-the-counter heartburn drug, pepcid, was shown to significantly decrease COVID symptoms in a 55-patient randomized trial authored by Dr. Tobias Janowitz and published in the BMJ journal Gut February 10, 2022. Famotidine has been...
Dr. Fernando Valerio, a critical care doctor in Honduras who co-authored a recent peer-reviewed study indicating the potential of repurposed drugs targeting SARS-CoV-2, shared with Trial Site his experience treating patients in the Central American nation....
Ivermectin and hydroxychloroquine, the cures in question, have proven to be ineffective in preventing or treating Covid-19 By Eric Berger Republican state lawmakers across the United States have proposed – and in some cases passed – legislation that they say keeps the...
Recently, an international trial site network known as the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) completed a global study revealing that remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2...
TFF Pharmaceuticals announced it has completed enrollment of 40 healthy subjects in its Phase 1 clinical trial of a dry powder formulation of niclosamide, an antiviral treatment with potential to address COVID-19 and other respiratory viral diseases. TFF develops...
Paxlovid, the oral Pfizer treatment for COVID-19, appears headed for emergency use authorization in Europe. Conditional Marketing Authorization for Paxlovid The European Medical Agency’s (EMA) human medicines committee (CHMP) recommended Pfizer Europe MA EEIG...
What if a relatively low-cost, repurposed drug could help treat multiple sclerosis (MS), the least treatable of all autoimmune diseases? That could be a distinct possibility now that Dr. Marcus Koch, MD, Ph.D., and Dr. Wee Yong, Ph.D., with Cummings School of Medicine...
With a great demand for antivirals targeting early-onset COVID-19, Merck inked a sub-licensing deal with one of the largest pharmaceutical companies in Bangladesh to produce Molnupiravir (Lagevrio) for distribution to over 100 nations. The deal, part of the Medicine...
BY MONIQUE BEALS Medicines Patent Pool, an organization supported by the U.N., announced on Thursday that over two dozen generic drug makers will soon begin producing Merck's COVID-19 pill to make the treatment more accessible in developing...
A research team led by Professor Hongzhe Sun, Norman & Cecilia Yip Professor in Bioinorganic Chemistry from the Department of Chemistry, Faculty of Science, the University of Hong Kong (HKU), in collaboration with Dr. Shuofeng Yuan, Assistant Professor from the...
New variants will pose continued threat, NIAID chief warns By John Bowden, Megan Sheets Dr Anthony Fauci warned at a Senate committee hearing that the US faced an “urgent need” for a so-called super vaccine that would be more effective at preventing new variants of...
By Matthew Stenger In an Israeli single-institution study reported in The Lancet Oncology, Ligumsky et al found that a booster dose of the SARS–CoV-2 Pfizer-BioNTech BNT162b2 mRNA vaccine given in August or September 2021 was immunogenic in patients receiving...